Nodofree (Dorzolamide Hydrochloride)

Dorzolamide hydrochloride blocks carbonic anhydrase in the ciliary body, reducing the production of aqueous humor. The resulting decrease in fluid volume lowers intra‑ocular pressure, which is essential in managing glaucoma and ocular hypertension.

The dosing regimen for Nodofree is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. The prescriber will provide specific instructions on the number of drops and frequency of administration.

Safety data for dorzolamide during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Nodofree.

To order Nodofree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nodofree (dorzolamide) belongs to the carbonic anhydrase inhibitor class, whereas many alternative drops are beta‑blockers or prostaglandin analogues. Dorzolamide reduces aqueous humor production, while beta‑blockers decrease fluid formation via adrenergic pathways and prostaglandins increase outflow. Choice depends on efficacy, tolerance, and patient‑specific factors.

Store Nodofree at room temperature, below 25 °C, in the original packaging. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing. Do not use the product if the solution appears discolored or contains particles.

Nodofree is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds to allow absorption.

Serious risks, though rare, include severe allergic reactions such as angio‑edema or anaphylaxis, corneal edema, sudden loss of vision, and life‑threatening skin reactions like Stevens‑Johnson syndrome. Any signs of these events require immediate medical attention.

Nodofree should be avoided in individuals with known hypersensitivity to dorzolamide, sulfonamides, or any component of the formulation. Patients with severe renal impairment or those who cannot discontinue systemic carbonic anhydrase inhibitors without medical supervision should also be evaluated carefully before use.